Drug Trial Radar · NCT06401213
A First-in-Human Safety Trial of MTX-463
Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Apr 15, 2024
Primary completion
Nov 15, 2024
Study completion Nov 15, 2024
Sponsor
- Lead sponsor
- Mediar TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- May 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.
Conditions
- Healthy
Interventions
MTX-463Biological
MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.
PlaceboOther
Matching Placebo-- Normal Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Related Adverse Events in healthy volunteersTime frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
- MTX-463 PK by dose will be evaluated for Cmax, as feasibleTime frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
- Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the study.Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
- MTX-463 PK by dose will be evaluated for AUC0-t, as feasible.Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
- MTX-463 PK by dose will be evaluated for AUC0-tau (MAD only), as feasibleTime frame: Through Day 82 (MAD Cohort)
- MTX-463 PK by dose will be evaluated for AUC0-∞, as feasibleTime frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.